AcelRx Pharmaceuticals, Inc. (ACRX) Lifted to Hold at ValuEngine
ValuEngine upgraded shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) from a sell rating to a hold rating in a report published on Monday, July 24th.
Several other brokerages also recently commented on ACRX. Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, July 11th. Jefferies Group LLC reissued a buy rating and issued a $7.00 price target on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. AcelRx Pharmaceuticals has an average rating of Hold and an average target price of $7.50.
Shares of AcelRx Pharmaceuticals (NASDAQ ACRX) traded down 1.67% on Monday, hitting $2.95. The stock had a trading volume of 468,777 shares. AcelRx Pharmaceuticals has a 1-year low of $1.95 and a 1-year high of $4.08. The firm has a 50-day moving average of $2.89 and a 200 day moving average of $2.79. The company’s market capitalization is $133.87 million.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.01. The firm had revenue of $2.66 million for the quarter, compared to the consensus estimate of $2.63 million. AcelRx Pharmaceuticals had a negative net margin of 319.19% and a negative return on equity of 478.66%. On average, equities analysts anticipate that AcelRx Pharmaceuticals will post ($1.13) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/19/acelrx-pharmaceuticals-inc-acrx-upgraded-to-hold-by-valuengine-updated-updated-updated.html.
In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $2.40, for a total transaction of $2,100,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 28.10% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. Teachers Advisors LLC boosted its stake in AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares during the last quarter. Acadian Asset Management LLC boosted its stake in AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 32,087 shares during the last quarter. ING Groep NV boosted its stake in AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 26,000 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after buying an additional 6,942 shares during the last quarter. Finally, WealthTrust Axiom LLC boosted its stake in shares of AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after buying an additional 70,000 shares in the last quarter. Hedge funds and other institutional investors own 30.37% of the company’s stock.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.